Condom use and HPV
This article was originally published in The Gray Sheet
Executive Summary
Results published in the June 22 New England Journal of Medicine suggest that condoms effectively reduce the risk of human papillomavirus (HPV) transmission. Investigators Rachel Winer, PhD, University of Washington, et al., report that women whose partners used condoms for all instances of intercourse over an eight-month period were 70% less likely to acquire a new infection than women whose partners used condoms less than 5% of the time. None of the women who reported always using condoms developed HPV lesions during the study period. Data also suggests that condom use aids in the prevention of high-grade cervical neoplasia and invasive cervical cancer, but larger data sets are needed to confirm these trends, the authors say. The investigation sheds light on questions raised by Congress about the accuracy of condom labeling for HPV and other sexually transmitted diseases (1"The Gray Sheet" Nov. 14, 2005, p. 17)...
You may also be interested in...
GAO reports on condom effectiveness against HPV
FDA is considering revised condom labeling stating that the devices may not protect against transmission of human papillomavirus (HPV) as well as they protect against other sexually transmitted diseases such as HIV, according to a recent report by the Government Accountability Office. The report responds to concerns raised earlier by Sen. Tom Coburn, R-Okla., who is a physician, as well as other members in Congress. Based on an FDA review, the report updates the results of a study published in the June 22, 2006, edition of the New England Journal of Medicine in which investigator Rachel Winer, University of Washington, found that women whose partners used condoms every time they had sex were 70% less likely to acquire a new infection of HPV than women whose partners used condoms less than 5% of the time ("1The Gray Sheet" June 26, 2006, In Brief). FDA concluded that there are limitations in existing condom labeling and identified several areas in which improved labeling would help provide reasonable assurance of safety and effectiveness
Regulatory News In Brief
Condom labeling: FDA proposes new latex condom labeling in a 1draft guidance and Federal Register 2notice posted on the agency's website Nov. 10. In 2000, Congress mandated FDA to reexamine condom labeling for medical accuracy, particularly with regard to the ability to provide protection from transmission of human papillomavirus (HPV). The labeling would indicate that latex condoms provide less protection for sexually transmitted diseases, such as HPV, which can be transmitted by contact with skin outside the area of condom coverage. But it would also note that condoms may provide some benefit in reducing the risk of HPV-related diseases, such as cervical cancer. Senator Tom Coburn (R-Okla.), who put a hold on Lester Crawford's nomination for FDA Commissioner in June because of FDA's delay in issuing the condom labeling guidelines, expressed dissatisfaction with the document. "The agency continues to promote inconclusive assurances that put women unknowingly at risk for cervical cancer, or worse," he said Nov. 10...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.